Board approves Dornier medical technology sale to Singapore
This article was originally published in Clinica
Executive Summary
The Dornier board has approved the sale of Dornier Medizintechnik to Singapore Technologies (see Clinica No 692, p 16). Despite reports of opposition to the sale among Dornier family members, they did not use their veto during a vote on the proposal, says Handelsblatt. The deal was due to be concluded during the week beginning February 19th and will be effective from March 1st.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.